Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07323784 · ClinicalTrials.gov registry record · Phase 2

A Study of NTX-1472 in Social Anxiety Disorder

A Phase 2 study of Social Anxiety Disorder (SAD), sponsored by Newleos Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
11
Study locations

NCT07323784 is a Phase 2 study of Social Anxiety Disorder (SAD) that is actively recruiting participants, run by Newleos Therapeutics. The registered enrollment target is 100 participants, below the 183-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (45% lower). The trial reports 11 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07323784, a Phase 2 study of Social Anxiety Disorder (SAD), is actively recruiting participants, sponsored by Newleos Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
11
Study locations

Study Summary

The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: * Take NTX-1472 or matching placebo every day for 8 weeks * Visit the clinic 6 times over the course of 14 weeks for checkups and tests

Conditions Studied

Social Anxiety Disorder (SAD)

Interventions

  • DRUG Placebo
  • DRUG NTX-1472

Study Locations (11)

California

  • SOAR Clinical Study Site - Encino
  • SOAR Clinical Study Site - Los Angeles
  • SOAR Clinical Study Site - Oceanside
  • SOAR Clinical Study Site - San Jose

Florida

  • SOAR Clinical Study Site - Jacksonville
  • SOAR Clinical Study Site - Tampa

Arizona

  • SOAR Clinical Study Site - Pheonix

Massachusetts

  • SOAR Clinical Study Site - Boston

New York

  • SOAR Clinical Study Site - Brooklyn

Tennessee

  • SOAR Clinical Study Site - Memphis

Texas

  • SOAR Clinical Study Site - Austin

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-12-09
Est. Completion 2027-01
Phase Phase 2

Sponsor

Newleos Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07323784

The ClinicalTrials.gov registry entry for NCT07323784 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (45% lower). The listed sponsor is Newleos Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Social Anxiety Disorder (SAD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07323784 reports 11 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT07323784 about?

NCT07323784 is a clinical study titled "A Study of NTX-1472 in Social Anxiety Disorder". The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does ...

What is the current status of trial NCT07323784?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-12-09. Estimated completion is 2027-01.

What conditions does trial NCT07323784 study?

This clinical trial studies the following conditions: Social Anxiety Disorder (SAD).

What interventions are being tested in trial NCT07323784?

The interventions under investigation include: Placebo (DRUG), NTX-1472 (DRUG).

Who is sponsoring clinical trial NCT07323784?

This trial is sponsored by Newleos Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07323784 being conducted?

This trial has 11 study locations across Arizona, California, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Social Anxiety Disorder (SAD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Social Anxiety Disorder (SAD)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.